AI improves efficiency and reduces costs in clinical trials for cancer treatments
Axios · August 12, 2026Original source ↗
What happened
A study by the Tufts Center for the Study of Drug Development found that AI can accelerate the clinical development of cancer drugs by approximately 10 weeks and reduce costs by up to $5.6 million in late-stage trials. The use of AI agents can enhance patient recruitment and data management, which may allow for more clinical studies.
Why it matters
The findings suggest that AI could help streamline clinical trials and potentially improve the development process for new cancer medications.
How this story affects people
How does this story affect you if you are involved in cancer research?
The use of AI in clinical trials could streamline the process of patient recruitment and data management, potentially leading to more efficient studies and a higher rate of successful drug development.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your RippleMore stories
- HealthEbola outbreak in Democratic Republic of Congo sees significant rise in cases and deaths
- HealthTrump proposes splitting combination vaccines into separate injections
- HealthEbola outbreak in DRC spreads to sixth province
- HealthSurrogate gives birth in Texas to baby with heart defect after fleeing from California